COMP <GO>
HRMY vs AUPH // 10Y YIELD & FRED MACRO BETA
Harmony Biosciences Holdings Inc. (NASDAQ) VS. Aurinia Pharmaceuticals Inc (NASDAQ) • 15-METRIC TALLY: HRMY 6
— AUPH 6
■ METRIC PARITY
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
macro-sensitivity
—
LAST: $17.21 (-0.86%) • MKT CAP: $2.29B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. AUPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | AUPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | 88.50% | -11.30 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | 16.50% | +46.50 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.8x | 21.1x | -13.30 | HRMY | /valuation <GO> |
| Free Cash Flow Yield | 15.48% | 5.92% | +9.56 | HRMY | /fcf-yield <GO> |
| Operating Margin | 24.00% | 37.10% | -13.10 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 68.00% | -49.70 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | 20.40% | +1.10 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | 8.33 | -2.95 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 49.5 | +1.58 | HRMY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 6.7x | +5.20 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.25B | $2.29B | -$42.5M | AUPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | AUPH REV | HRMY GROSS % | AUPH GROSS % | HRMY FCF | AUPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $283.1M | 77.2% | 88.5% | $347.9M | $135.7M |
| FY 2024 | $714.7M | $235.1M | 78.1% | 88.0% | $218.7M | $44.4M |
| FY 2023 | $582.0M | $175.5M | — | — | $219.4M | -$33.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
AUPH // BETA —